Clinical trials: Autotransplantation
Spondylolisthesis, Scoliosis
A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
OsteoAMP is a novel allograft bone graft substitute (BGS) that has been processed to retain multiple endogenous growth factors for use in spinal fusion.
- Conditions
- Spondylolisthesis, Scoliosis, Intervertebral Disc Disease
- Trial name
- NCT02225444
- Testing
- OsteoAMP
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Bioventus LLC
Diabetes Mellitus, Type 2
Autologous Islet Transplantation for Diabetes
This study aims to conduct an exploratory clinical trial recruiting insulin-dependent diabetic patients who meet the criteria for islet transplantation.
- Trial name
- APPITD (NCT07118475)
- Testing
- Autologous islet transplantation
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Zhongshan Hospital
Anterior Cruciate Ligament Rupture
Adductor Canal Block and IPACK Block vs. Isolated Adductor Canal Block for Post-Operative Analgesia Following ACL Reconstruction With Bone Patellar Tendon Bone Autograft:
A randomized, single-blind, single-center study measuring the effects of adductor canal block combined with IPACK infiltration compared to adductor canal block alone on post-operative pain and opioid consumption in patients…
- Trial name
- NCT05286307
- Testing
- IPACK block
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- NYU Langone Health
Multiple Myeloma
MInimal Residual Disease Adapted Strategy
IFM 2020-02 will enroll patients eligible for ASCT less than 66 years. All patients will receive induction based on 6 cycles (28-day) of KRD-Isatuximab (Isa-KRD), in order to achieve deep responses and high MRD negativity rates.
- Trial name
- MIDAS (NCT04934475)
- Testing
- Isatuximab, ASCT
- Where
- 73 sites in Belgium, France and 1 more
- Volunteers
- 791 people
- Sponsor
- Intergroupe Francophone du Myelome
Apicomarginal Defects
Healing of Apicomarginal Defects Using Autograft or Allograft With Collagen Membrane
Apicomarginal defects, which connect apical and marginal bone loss, are difficult to manage surgically due to their limited regenerative potential.
- Trial name
- NCT07412067
- Testing
- Guided tissue regeneration
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Parathyroid Autologous Transplantation
Parathyroid Auto-transplantation: Prospective Randomized Trial of the Personalized Site
The functional parathyroid auto-transplantation (PA) could release parathyroid hormone (PTH) into the circulatory system of the body through the capillaries.
- Trial name
- NCT02906748
- Testing
- injection with a syringe in new-site for parathyroid autografting, injection with a syringe in traditional site for parathyroid autografting
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Tongji Hospital
Anterior Cruciate Ligament Injuries, Knee Injuries
Graft Type and Outcomes After ACL Reconstruction in Female Athletes
This prospective multicenter cohort study aims to compare clinical and functional outcomes between hamstring tendon and quadriceps tendon autografts in anterior cruciate ligament (ACL) reconstruction in female athletes.
- Trial name
- LCA-WOMEN (NCT07722104)
- Testing
- Hamstring tendon autograft ACL reconstruction, Quadriceps tendon autograft ACL reconstruction
- Where
- Spain
- Volunteers
- 82 people
- Sponsor
- Universidad Católica San Antonio de Murcia
Sickle Cell Disease
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle…
- Trial name
- NCT04443907
- Testing
- OTQ923
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
This study is a single-center, open-label study of high-dose Melphalan HCl (hydrochloric acid) for injection (propylene glycol-free Melphalan) conducted in 24 patients, who have symptomatic multiple myeloma and qualify for…
- Trial name
- NCT02669615
- Testing
- Melphalan HCl for injection (propylene glycol free)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
Ross Operation, Pulmonary Autograft
Ross Operation Failure Database
A large multicentric registry to obtain data to analyse the pulmonary autograft (PA) failure phenomenon and feed more complex biomechanical models to be integrated with clinical imaging with the final aim to predict Ross…
- Conditions
- Ross Operation, Pulmonary Autograft, Structural Valve Degeneration
- Trial name
- ROFDA (NCT03027804)
- Testing
- Ross Operation
- Where
- France
- Sponsor
- Centre Cardiologique du Nord
Multiple Myeloma
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF…
- Trial name
- NCT06514508
- Testing
- Motixafortide+G-CSF
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
Non-Hodgkin's Lymphoma
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
The purpose of this study is to evaluate the ability of two different fixed doses of pegfilgrastim (6mg and 12mg) and a by-weight dose of filgrastim (5ug/kg/day) for the mobilisation and collection of PBPCs for autologous…
- Trial name
- NCT00117455
- Testing
- pegfilgrastim, filgrastim
- Sponsor
- Amgen
Neuromyelitis Optica, Devic's Disease
Autologous Transplant To End NMO Spectrum Disorder
This study is designed to treat your disease with an autologous stem cell transplant using a regimen of immune suppressant drugs and chemotherapy to reset your immune system and to determine if your disease will go into long-term…
- Conditions
- Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
- Trial name
- ATTEND (NCT03829566)
- Testing
- Rituximab, Cyclophosphamide, Mesna
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Multiple Sclerosis, Relapsing-Remitting
Optimal Conditioning Regimen for Autologous Transplantation of Relapsing Remitting Multiple Sclerosis
This study is designed to compare two non-myeloablative conditioning regimens (combination of chemotherapy and immune specific proteins against immune cells) for relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT05482542
- Testing
- Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab
- Where
- United States
- Sponsor
- Scripps Health
Limbal Stem Cell Deficiency
Autologous Transplantation of Cultivated Limbal Stem Cells on Amniotic Membrane in Limbal Stem Cell Deficiency (LSD) Patients
The purpose of this study is to evaluate the efficacy, safety, and long term outcomes of ex vivo cultured limbal stem cell on amniotic membrane transplantation for corneal surface reconstruction in cases of partial and sever…
- Trial name
- NCT00736307
- Testing
- Cultured limbal stem cells Transplantation
- Where
- 2 sites in Iran
- Volunteers
- 10 people
- Sponsor
- Royan Institute
Multiple Myeloma
Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to generate anti-myeloma T-cells which will kill myeloma cells and nothing else.
- Trial name
- NCT00090493
- Testing
- MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Arkansas
Burn Degree Second, Burn Degree Third
The Use of Cultured (Dermal) Epithelial Autografts in Severely Burned Patients
The Swisskera project is a multicenter follow-up study at the three Swiss burn centers evaluating long-term outcomes after burn wound coverage with lab-grown epithelial grafts, specifically cultured epithelial autograft (CEA)…
- Conditions
- Burn Degree Second, Burn Degree Third, Skin Transplantation, Full Thickness Skin Defects
- Trial name
- Swisskera (NCT07415577)
- Testing
- Standard of Care (SOC)
- Where
- 3 sites in Switzerland
- Volunteers
- 236 people
- Sponsor
- University Children's Hospital, Zurich
Lymphoma
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells.
- Trial name
- NCT00005998
- Testing
- carmustine, cyclophosphamide, cytarabine
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hypocalcemia, Hypoparathyroidism
NIRAF-Guided Parathyroid Identification During Thyroidectomy
This is a single-site, two-component prospective study evaluating whether near-infrared autofluorescence (NIRAF) imaging can improve intraoperative identification of parathyroid glands during thyroidectomy and reduce…
- Conditions
- Hypocalcemia, Hypoparathyroidism, Thyroid Diseases, Goiter, Nodular
- Trial name
- NCT07617584
- Testing
- Wearable Near-Infrared Autofluorescence Imaging System
- Where
- North Macedonia
- Volunteers
- 280 people
- Sponsor
- Ss. Cyril and Methodius University of Skopje
Multiple Myeloma and Plasma Cell Neoplasm
Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma
RATIONALE: Activating white blood cells in the laboratory may help them kill more cancer cells when they are put back in the body.
- Trial name
- NCT00566098
- Testing
- MILs, Melphalan, PCV13
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins